Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  For the Patient  |  Careers at Hemispherx  


 

Hemispherx Biopharma Investor Relations

Welcome to Hemispherx Biopharma Investor Relations! In this section you can view the most recent Hemispherx press releases, SEC filings, including the 10K & 10Q, as well as obtain the contact information for the Company's Investor Relations contact, transfer agent and auditor. You may also request to receive news releases by e-mail as well as corporate materials mailed to you.

Recent News:

 

6/24/2009 Hemispherx Biopharma Reports on Annual Stockholder Meeting

6/17/2009 Hemispherx Biopharma appoints Robert Dickey IV to the new position of Senior Vice President
Role to facilitate strategic partnering and clinical progress

6/16/2009 Hemispherx Biopharma Provides Corporate Update on Various Strategic Initiatives
6/12/2009 Hemispherx’s Collaborative Partner in Japan, Biken Corp., Expands Production Capacity for Swine/Avian Flu Vaccines …WHO Raises Threat of Swine Flu to Pandemic Level

6/4/2009 Japanese National Institute of Infectious Diseases Scientists Identify Hemispherx Biopharma’s Drug Technology as the “Most Promising Mucosal Adjuvant for Influenza”
.....Topical Application Also Affords Strong Cross-Protection against Variant Flu Strains

More Releases...

Click Here for a complete archive

Transfer Agent

Continental Stock Transfer & Trust Company
Shareowner Services
2 Broadway
New York, New York 10004 
Tel: 212-509-4000
Fax: 212-509-5150

Independent Public Accountants

 McGladrey & Pullen, LLP

 

Investor Relations:

Dianne Will
Phone:  518-398-6222
Fax:  518-398-6369
or send an e-mail to:
ir@hemispherx.net

 

 

 

Information contained on the Hemispherx website other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed on the Hemispherx website and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgement as of the date of this website. The Company disclaims, however, any intent or obligation to update these forward-looking statements.